BIM-23190

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BIM-23190 

BIM-23190 是 somatostatin 的类似物，是 SSTR2 和 SSTR5 的选择性激动剂，对SSTR2 和SSTR5 的Ki 值分别为 0.34 nM 和 11.1 nM。BIM-23190 可用于糖尿病和癌症研究。

BIM-23190

BIM-23190 Chemical Structure

CAS No. : 182153-96-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly[1][3].

体外研究
(In Vitro)

BIM-23190 tends to mildly stimulate PRL secretion[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

BIM-23190 (50 μg/mouse, twice a day) exhibits significant anti-tumor (C6 glioma) activity[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male athymic nude (nu/nu) mice, 5-6 wk old (C6 glioma)[2].
Dosage: 50 μg/mouse
Administration: Injected twice a day for 19 days.
Result: Significantly reduced the tumor growth rate.

分子量

1202.45

Formula

C57H79N13O12S2
CAS 号

182153-96-4
Sequence

{4-(2-Hydroxyethyl)-1-piperazinylacetyl}-{D-Phe}-Cys-Tyr-{D-Trp}-Lys-{Abu}-Cys-Thr-NH2 (Disulfide bridge: Cys2-Cys7)
Sequence Shortening

{4-(2-Hydroxyethyl)-1-piperazinylacetyl}-{D-Phe}-CY-{D-Trp}-K-{Abu}-CT-NH2 (Disulfide bridge: Cys2-Cys7)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92.

    [2]. Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88.

    [3]. T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务